Poster Walk II: Application of Quantitative Approaches for Predicting Patient Outcomes brought to you by Johnson & Johnson

PWII-001 MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)
R. Franzese¹, L. Qin², S. Fu², B. Rich³, M. Zierhut⁴, S. Visser⁵; ¹GSK, Nashville, TN, USA, ²Certara, ³InnoMx, ⁴Certara, Princeton - NJ, USA, ⁵GSK.

PWII-002 EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
L. Chekka¹, D. Samarth¹, E. Mohamed¹, Y. Guo¹, W. Wheeler², S. Schrieber¹, J. Florian¹, Y. Wang³, D. Strauss¹, P. Hyland¹; ¹U.S. Food and Drug Administration, ²IMS Inc, ³U.S. Food and Drug Administration, Silver Spring, United States.

PWII-003 MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS
B. Remaily¹, Y. Guo¹, A. Adeluola², G. Young¹, T. Vu¹, J. Thomas¹, K. Kim¹, Z. Xie¹, G. Mulcahy¹, C. Stanton¹, M. Manna¹, J. Na¹, S. Kulp¹, L. Ganesan¹, C. Coss¹, T. Mace¹, D. Owen¹, M. Phelps¹; ¹The Ohio State University, ²The Ohio State University, Columbus, OH.

PWII-004 DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
H. Park¹, G. Mugundu², A. Singh²; ¹Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center, ²Takeda Pharmaceuticals.

PWII-005 PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
E. Velasquez, S. Vadhavkar, N. Kassir, D. Kuruvilla; Genentech.

Brought to you by:



This event is sponsored by an ASCPT Partner organization. ASCPT partners were not involved in the development or content of this program.